

Patient Information		
Surname:	Given name(s):	
Date of birth:	PHN:	

## Patient Agreement

I UNDERSTAND AND AGREE THAT:

- □ I am being started/continued on buprenorphine/naloxone (often called Suboxone®) for the treatment of opioid addiction. While I may choose to taper off this treatment at any time, I understand that most patients benefit from at least one year of treatment or longer.
- □ While I am receiving buprenorphine/naloxone treatment, I will only get opioid prescriptions from my buprenorphine/naloxone prescriber and will not get any from other doctors or clinics.
- □ For my safety, I give consent to my buprenorphine/naloxone prescriber to communicate with my pharmacist and any other physicians involved in my care, and to check my PharmaNet profile.
- I can expect confidentiality about my treatment from my doctor and other healthcare providers. My personal information will not be shared except with other healthcare providers as I agreed to above.
- □ I will work with my buprenorphine/naloxone prescriber to develop a treatment plan and set goals. We will review regularly and change them as needed.
- □ In addition to buprenorphine/naloxone, I can participate in counselling or peer-support groups and other programs, as part of my treatment plan. My buprenorphine/naloxone prescriber will give me information about the options and programs available in my community.
- □ I can choose my clinic and pharmacy and can decide to change either if necessary.
- □ I can decide if I want to continue, stop or change my treatment plan at any time. I agree to make this decision with my prescriber.
- □ Beginning buprenorphine/naloxone treatment may require daily trips to the pharmacy and regular visits to my prescriber, which may impact my work, school or other responsibilities.
- My prescriber may need to make changes to my treatment plan to provide the safest and best possible care. These changes might include dosage, how often I pick up my medication, how often I visit the clinic, and how often my urine is tested. Until I am stable, I will receive buprenorphine/ naloxone through daily witnessed ingestion at a pharmacy or another healthcare provider.

## Patient Agreement (continued)

- Once I am stable, my prescriber will work with me to determine if take-home doses are appropriate.
- □ I will not give my prescriptions or medications to anyone else.
- □ I will not take my medication more often or at higher doses than my prescription states.
- □ I am the only person who may pick up my buprenorphine/naloxone prescription from the pharmacy.
- Missing more than one dose of buprenorphine/naloxone may lead to withdrawal, and missing more than 6 consecutive daily doses may cause a loss of tolerance to buprenorphine/naloxone, requiring that I take a lower dose until I stabilize.
- □ If I do not pick up my buprenorphine/naloxone from the pharmacy for 3 or more consecutive days, my prescription may be cancelled until my prescriber has been told the reason for my missed doses. I may receive a lower dose of buprenorphine/naloxone after multiple missed doses to prevent overdose.
- □ Like any prescribed medication, the pharmacy cannot replace my medication if it is lost or stolen. I cannot pick my medication up early from the pharmacy.
- □ I will not be cut off from treatment. If buprenorphine/naloxone is not providing the results expected, my prescriber will work with me to try other medications. If my prescriber can no longer provide care for me, they will refer me to another person who can.

## I UNDERSTAND THAT I AM EXPECTED TO:

- Abstain from opioid use for 12-24 hours before I begin treatment with buprenorphine/naloxone, and that I will need to work with my doctor closely when first starting buprenorphine/naloxone. Those currently taking methadone may need to abstain longer than 72 hours.
- □ Provide urine for drug testing on a regular basis.
- Provide urine samples at the clinic and that these samples are not to be altered. Urine samples that are cold or appear to have been altered will be treated as a serious issue and may affect my treatment plan and ability to receive take-home doses.
- Avoid using alcohol or other drugs, such as prescription or over the counter opioid medications, sleeping pills, or tranquilizers. I understand that combining alcohol or these medications with buprenorphine/naloxone can lead to overdose and other serious harms and may affect my treatment plan and ability to receive take-home doses.
- □ Notify any health care provider that I receive care from that I am taking buprenorphine/naloxone.
- Do my best to keep appointments as scheduled. I understand that missing or skipping scheduled appointments may affect my treatment plan and ability to receive take-home doses.
- □ Take my medication as prescribed. I understand that buprenorphine/naloxone contains naloxone which will cause immediate withdrawal if injected or snorted.
- □ Treat others and be treated with respect. I understand that treating staff with disrespect for any reason is unacceptable and may lead to discharge from the program.
- □ Keep a Narcan (naloxone) kit on hand in case of overdose and receive training in how to use it.
- Notify my primary care provider if I become pregnant (if applicable)
  I understand that for safety I must inform my prescriber if I am pregnant, suspect I may be pregnant, or if I am planning a pregnancy.

Patient Identified Goals		

## Prescriber Agreement

I confirm that:

- □ This form has been reviewed in detail with the patient and they understand its content fully. This should be reviewed again when the patient is not in withdrawal.
- □ The patient was given time to ask questions and seek clarification before signing this document.
- □ The evidence for other treatment options was reviewed, and the patient agrees to buprenorphine/naloxone.
- □ Information and resources to support psychosocial treatment interventions and supports will be provided to the patient.
- □ PharmaNet was reviewed to identify other prescribed medications, and will be checked at each subsequent appointment.
- □ It is my responsibility to decrease the possibility of diversion. If and when the patient is assessed as ready to receive take-home doses, guideline standards for random urine drug tests and medication checks will be pursued and clinical judgement used in an effort to limit risks of diversion.
- □ A treatment plan with clear goals was developed with the patient, and will be reviewed and documented regularly during treatment.

Consent	
Patient's signature:	Date:
Prescriber's signature:	Date:







